Pregnancy and lactation: Rosuvastatin is contraindicated during pregnancy or lactation as the safety of Rosuvastatin during pregnancy and whilst breast-feeding has not been established. Women of child-bearing potential should use appropriate contraceptive measures. Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. If a patient becomes pregnant during the use of this product, treatment should be discontinued immediately.
There are no data with respect to excretion in milk in humans.